MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 413952 | Name: Bifeprunox Free Base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bifeprunox Free Base is an antipsychotic agent.

Chemical Structure

Bifeprunox Free Base
Bifeprunox Free Base
CAS#350992-10-8 (free base)

Theoretical Analysis

MedKoo Cat#: 413952

Name: Bifeprunox Free Base

CAS#: 350992-10-8 (free base)

Chemical Formula: C24H23N3O2

Exact Mass: 385.1790

Molecular Weight: 385.47

Elemental Analysis: C, 74.78; H, 6.01; N, 10.90; O, 8.30

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
350992-10-8 (free base) 350992-13-1 (mesylate)
Synonym
Bifeprunox Free Base; DU127090; DU-127090; DU 127090
IUPAC/Chemical Name
7-(4-(Biphenyl-3-ylmethyl)piperazin-1-yl)benzoxazol-2(3H)-one
InChi Key
CYGODHVAJQTCBG-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H23N3O2/c28-24-25-21-10-5-11-22(23(21)29-24)27-14-12-26(13-15-27)17-18-6-4-9-20(16-18)19-7-2-1-3-8-19/h1-11,16H,12-15,17H2,(H,25,28)
SMILES Code
O=C1OC2=C(N3CCN(CC4=CC(C5=CC=CC=C5)=CC=C4)CC3)C=CC=C2N1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 385.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Chattopadhyay A, Frey S, Green G. Bifeprunox versus placebo for schizophrenia. Cochrane Database Syst Rev. 2016 Oct 12;10(10):CD012029. doi: 10.1002/14651858.CD012029.pub2. PMID: 27732740; PMCID: PMC6457956. 2: Chattopadhyay A, Frey S, Green G, Harkness A, McDermott A, Yates A. Bifeprunox vs Placebo for Schizophrenia. Schizophr Bull. 2016 Jul;42(4):881-2. doi: 10.1093/schbul/sbw048. Epub 2016 May 6. PMID: 27153863; PMCID: PMC4903068. 3: Newman-Tancredi A, Cussac D, Depoortere R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr Opin Investig Drugs. 2007 Jul;8(7):539-54. PMID: 17659474. 4: Etievant A, Bétry C, Arnt J, Haddjeri N. Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation. Neurosci Lett. 2009 Aug 21;460(1):82-6. doi: 10.1016/j.neulet.2009.05.035. Epub 2009 May 18. PMID: 19450663. 5: De Santis M, Pan B, Lian J, Huang XF, Deng C. Different effects of bifeprunox, aripiprazole, and haloperidol on body weight gain, food and water intake, and locomotor activity in rats. Pharmacol Biochem Behav. 2014 Sep;124:167-73. doi: 10.1016/j.pbb.2014.06.004. Epub 2014 Jun 13. PMID: 24933333. 6: Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology (Berl). 2008 Oct;200(3):317-31. doi: 10.1007/s00213-008-1207-7. Epub 2008 Jul 4. PMID: 18597078. 7: Di Clemente A, Franchi C, Orrù A, Arnt J, Cervo L. Bifeprunox: a partial agonist at dopamine D2 and serotonin 1A receptors, influences nicotine-seeking behaviour in response to drug-associated stimuli in rats. Addict Biol. 2012 Mar;17(2):274-86. doi: 10.1111/j.1369-1600.2011.00319.x. Epub 2011 Apr 26. PMID: 21521422. 8: Dahan L, Husum H, Mnie-Filali O, Arnt J, Hertel P, Haddjeri N. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour. J Psychopharmacol. 2009 Mar;23(2):177-89. doi: 10.1177/0269881108089586. Epub 2008 May 30. PMID: 18515444. 9: Cosi C, Carilla-Durand E, Assié MB, Ormiere AM, Maraval M, Leduc N, Newman- Tancredi A. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur J Pharmacol. 2006 Mar 27;535(1-3):135-44. doi: 10.1016/j.ejphar.2006.01.051. Epub 2006 Mar 22. PMID: 16554049. 10: Spiros A, Carr R, Geerts H. Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse. Neuropsychiatr Dis Treat. 2010 Sep 7;6:589-603. doi: 10.2147/NDT.S12460. PMID: 20856922; PMCID: PMC2938308.